| Literature DB >> 17280754 |
Anthony H-C Choi1, Kristi Smiley, Mitali Basu, Monica M McNeal, Mingyuan Shao, Judy A Bean, John D Clements, Richard R Stout, Richard L Ward.
Abstract
Mucosal administration (intranasal or oral) of a VP6 rotavirus vaccine to mice consistently elicits high levels of protection after rotavirus challenge (93->99% reductions in fecal rotavirus shedding) but only when co-administered with an effective adjuvant such as LT(R192G). Here, we showed that Biojector needle-free injection of VP6-encoded plasmids also induced protection (85-93%) when they were co-administrated with LT(R192G)-encoded plasmids. A reduction in the amount of VP6 plasmid from 50 to 10 microg reduced protection from 93 to 70%, but the immunized mice remained significantly (P<0.05) protected. Intramuscular needle injection of VP6/LT(R192G)-plasmids also induced significant protection (66%).Entities:
Mesh：
Substances：
Year: 2007 PMID： 17280754 PMCID： PMC1906844 DOI： 10.1016/j.vaccine.2007.01.035
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641